July 2024
1. CHERTOW GM, Chang AM, Felker GM, Heise M, et al
   Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
   Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03156.
   

   >> Share

   
   June 2024
2. MANN JFE, Rossing P, Bakris G, Belmar N, et al
   Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
   Nat Med. 2024 Jun 24. doi: 10.1038/s41591-024-03133.
   

   >> Share

   
   May 2024
3. CHERTOW GM, Chang AM, Felker GM, Heise M, et al
   IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
   Nat Med. 2024 May 25. doi: 10.1038/s41591-024-03043.
   

   >> Share

   
   
4. KONDO T, Jhund PS, Gasparyan SB, Yang M, et al
   A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials.
   Nat Med. 2024;30:1432-1439.
   

   >> Share

   
   February 2024
5. WEITZ JI, Tanko LB, Floege J, Fox KAA, et al
   Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial.
   Nat Med. 2024;30:435-442.
   

   >> Share

   
   July 2023
6. INKER LA, Collier W, Greene T, Miao S, et al
   A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
   Nat Med. 2023;29:1867-1876.
   

   >> Share

   
   June 2022
7. 
   Cross-ancestry genome-wide polygenic score predicts chronic kidney disease.
   Nat Med. 2022 Jun 23. pii: 10.1038/s41591-022-01871.
   

   >> Share

   
   
8. KHAN A, Turchin MC, Patki A, Srinivasasainagendra V, et al
   Genome-wide polygenic score to predict chronic kidney disease across ancestries.
   Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01869.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share